Nephrology Department, Guangzhou Women and Children's Medical Center, Guangzhou City 510623, China.
Graduate School, Ningxia Medical University, Yinchuan City 750000, China.
Biomed Res Int. 2020 Mar 23;2020:5281251. doi: 10.1155/2020/5281251. eCollection 2020.
Angiopoietin-like protein 4 (ANGPTL4) is widely known as a key regulator of lipid metabolism. We investigated the relationship between ANGPTL4 expression in serum or urine and blood lipid or urine protein levels of patients with hyperlipidemia- (HL-) related proteinuria. Sixty-eight patients with HL-related proteinuria (HL-Pro group), 68 patients with HL without proteinuria (HL-NPro group), 46 patients with non-HL-related proteinuria (NHL-Pro group), and 50 healthy control (Con) subjects were selected. There were no significant differences in serum ANGPTL4 levels between the Con group (36.82 ± 17.03 ng/ml) and the HL-Pro group (27.94 (18.90, 53.72) ng/ml). Additionally, the serum ANGPTL4 levels in the HL-Pro group were significantly lower than those in the HL-NPro group (53.32 ± 24.01 ng/ml) ( < 0.001). The urine ANGPTL4/Cr levels in the HL-Pro group (52.01 (45.25, 79.79) g/g) were significantly higher than those in the HL-NPro group (9.96 (8.35, 12.43) ng/ml) ( < 0.05). A significant alteration in urine ANGPTL4/Cr levels was observed in the NHL-Pro group (69.41 ± 55.36 g/g) and the Con group (10.08 ± 2.38 g/g) as well. There was no correlation between serum and urine ANGPTL4 levels of the four groups ( > 0.05). Serum ANGPTL4 levels (HL-Pro/HL-NPro group) were positively correlated with total cholesterol (TC) and triglyceride (TG) levels in hyperlipidemia patients. However, there was no correlation between urinary ANGPTL4 levels and TC or TG ( > 0.05). Urine ANGPTL4 levels were positively correlated with 24hUPro in patients with renal impairment (HL-Pro/NHL-Pro group). To summarize, ANGPTL4 may be considered an accurate predictor of proteinuria with HL. Notably, serum or urine ANGPTL4 levels indicated the degree of proteinuria or hyperlipidemia, respectively, in HL patients.
血管生成素样蛋白 4 (ANGPTL4) 广泛被认为是脂质代谢的关键调节因子。我们研究了血清或尿液中 ANGPTL4 的表达与高脂血症相关蛋白尿(HL-相关蛋白尿)患者的血脂或尿蛋白水平之间的关系。选择了 68 例 HL-相关蛋白尿患者(HL-Pro 组)、68 例 HL 无蛋白尿患者(HL-NPro 组)、46 例非 HL 相关蛋白尿患者(NHL-Pro 组)和 50 名健康对照(Con)。Con 组(36.82±17.03ng/ml)和 HL-Pro 组(27.94(18.90,53.72)ng/ml)之间血清 ANGPTL4 水平无显著差异。此外,HL-Pro 组的血清 ANGPTL4 水平明显低于 HL-NPro 组(53.32±24.01ng/ml)(<0.001)。HL-Pro 组的尿 ANGPTL4/Cr 水平(52.01(45.25,79.79)g/g)明显高于 HL-NPro 组(9.96(8.35,12.43)ng/ml)(<0.05)。NHL-Pro 组和 Con 组的尿 ANGPTL4/Cr 水平(69.41±55.36g/g 和 10.08±2.38g/g)也有显著改变。四组间血清和尿 ANGPTL4 水平无相关性(>0.05)。高脂血症患者血清 ANGPTL4 水平(HL-Pro/HL-NPro 组)与总胆固醇(TC)和甘油三酯(TG)水平呈正相关。然而,尿 ANGPTL4 水平与 TC 或 TG 无相关性(>0.05)。尿 ANGPTL4 水平与肾功能损害患者的 24hUPro 呈正相关(HL-Pro/NHL-Pro 组)。综上所述,ANGPTL4 可能是 HL 相关蛋白尿的准确预测因子。值得注意的是,血清或尿 ANGPTL4 水平分别提示 HL 患者的蛋白尿或高脂血症程度。